HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Ventricular tachyarrhythmia — Clinical Guidelines

Overview

Ventricular tachyarrhythmias (VT) are rapid heart rhythms originating in the ventricles, significantly contributing to sudden cardiac death 1. These arrhythmias can be induced by various factors including myocardial ion channel diseases and psychological stress 1 19.

Diagnosis

Electrocardiogram (ECG): Essential for identifying VT patterns 4 12.

Holter Monitoring: Useful for detecting intermittent VT episodes 22.

Electrophysiology Study: Evaluates arrhythmia mechanisms and inducibility 17 24.

QT Dispersion and Signal-Averaged ECG: Predict susceptibility to VT 13.

T Wave Alternans (TWA): Identifies arrhythmic vulnerability 4.

Management

Implantable Cardioverter-Defibrillator (ICD): Recommended for high-risk patients 8 18.

Antiarrhythmic Drugs:

- Beta-Blockers: Reduce VT recurrence 15 2. - Amiodarone: Effective in treating refractory VT 7 12. - Sotalol: Comparable efficacy to amiodarone in some studies 10 11.

Radiofrequency Catheter Ablation: Suitable for specific VT subtypes 8.

Magnesium Therapy: Beneficial in normomagnesemic patients with refractory VT 25.

Special Populations

Elderly: ICD efficacy and safety profiles need careful consideration 18.

Comorbidities: Preoperative evaluation crucial for patients with underlying heart disease 23.

Key Recommendations

ICD Implantation for High-Risk Patients: Recommended for those with sustained VT or aborted cardiac arrest 8 (Evidence: Strong).

Beta-Blockers as First-Line Therapy: Effective in reducing VT recurrence in ICD recipients 15 2 (Evidence: Moderate).

Consider Amiodarone for Refractory VT: Particularly useful in patients unresponsive to other antiarrhythmic drugs 7 12 (Evidence: Moderate).

Serial Electrophysiology Studies: Can predict efficacy of serial drug testing in VT management 17 (Evidence: Moderate).

Holter Monitoring for VT Surveillance: Useful for detecting asymptomatic VT episodes 22 (Evidence: Moderate).

References

1 Xie D, Wu J, Wu Q, Zhang X, Zhou D, Dai W et al.. Integrating proteomic, lipidomic and metabolomic data to construct a global metabolic network of lethal ventricular tachyarrhythmias (LVTA) induced by aconitine. Journal of proteomics 2021. link 2 Schupp T, Behnes M, Kim SH, Müller J, Weidner K, Reiser L et al.. Comparable risk of recurrent ventricular tachyarrhythmias in implantable cardioverter-defibrillator recipients treated with single beta-blocker or combined amiodarone. Basic & clinical pharmacology & toxicology 2021. link 3 Haraguchi R, Ashihara T, Namba T, Tsumoto K, Murakami S, Kurachi Y et al.. Transmural dispersion of repolarization determines scroll wave behavior during ventricular tachyarrhythmias. Circulation journal : official journal of the Japanese Circulation Society 2011. link 4 Kim JW, Pak HN, Park JH, Nam GB, Kim SK, Lee HS et al.. Defibillator electrogram T wave alternans as a predictor of spontaneous ventricular tachyarrhythmias in defibrillator recipients. Circulation journal : official journal of the Japanese Circulation Society 2009. link 5 Akiyama T, Powell JL, Mitchell LB, Ehlert FA, Baessler C. Resumption of driving after life-threatening ventricular tachyarrhythmia. The New England journal of medicine 2001. link 6 Kassotis J, Yusupova M, Thoben D, Stawiarski M, Reddy CV. Syncope masquerading as a panic disorder: role of the subcutaneous loop recorder in eliciting the appropriate diagnosis. Pacing and clinical electrophysiology : PACE 2001. link 7 Yeih DF, Chiang FT, Huang SK. Successful treatment of aconitine induced life threatening ventricular tachyarrhythmia with amiodarone. Heart (British Cardiac Society) 2000. link 8 Farré J, Cabrera JA, Romero J, Rubio JM. Therapeutic decision tree for patients with sustained ventricular tachyarrhythmias or aborted cardiac arrest: a critical review of the Antiarrhythmics Versus Implantable Defibrillator trial and the Canadian Implantable Defibrillator Study. The American journal of cardiology 2000. link01291-1) 9 Mattioni TA, Nademanee K, Brodsky M, Fisher J, Riggio D, Allen B et al.. Initial clinical experience with a fully automatic in-hospital external cardioverter defibrillator. Pacing and clinical electrophysiology : PACE 1999. link 10 Naitoh N, Yamaura M, Tagawa M, Aizawa Y. A comparison of electrophysiologic properties between responders and non-responders to DL-sotalol among patients with ventricular tachyarrhythmia. Importance of the lack of a reverse use-dependent effect on ventricular refractoriness to responders. Japanese heart journal 1998. link 11 Seidl K, Hauer B, Schwick NG, Zahn R, Senges J. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. The American journal of cardiology 1998. link00478-0) 12 Korth-Bradley JM, Rose GM, de Vane PJ, Peters J, Chiang ST. Population pharmacokinetics of intravenous amiodarone in patients with refractory ventricular tachycardia/fibrillation. Journal of clinical pharmacology 1996. link 13 Goldner B, Brandspiegel HZ, Horwitz L, Jadonath R, Cohen TJ. Utility of QT dispersion combined with the signal-averaged electrocardiogram in detecting patients susceptible to ventricular tachyarrhythmia. The American journal of cardiology 1995. link80337-3) 14 Fei L, Statters DJ, Anderson MH, Malik M, Camm AJ. Relationship between short- and long-term measurements of heart rate variability in patients at risk of sudden cardiac death. Pacing and clinical electrophysiology : PACE 1994. link 15 Leclercq JF, Leenhardt A, Coumel P, Slama R. Efficacy of beta-blocking agents in reducing the number of shocks in patients implanted with first-generation automatic defibrillators. European heart journal 1992. link 16 Kou WH, Kirsh MM, Bolling SF, Stirling M, Kadish AH, De Buitleir M et al.. Effect of antiarrhythmic drug therapy on the incidence of shocks in patients who receive an implantable cardioverter defibrillator after a single episode of sustained ventricular tachycardia/fibrillation. Pacing and clinical electrophysiology : PACE 1991. link 17 Kuchar DL, Rottman J, Berger E, Freeman CS, Garan H, Ruskin JN. Prediction of successful suppression of sustained ventricular tachyarrhythmias by serial drug testing from data derived at the initial electrophysiologic study. Journal of the American College of Cardiology 1988. link90465-2) 18 Mercando AD, Furman S, Johnston D, Frame R, Brodman R, Kim SG et al.. Survival of patients with the automatic implantable cardioverter defibrillator. Pacing and clinical electrophysiology : PACE 1988. link 19 Brodsky MA, Sato DA, Iseri LT, Wolff LJ, Allen BJ. Ventricular tachyarrhythmia associated with psychological stress. The role of the sympathetic nervous system. JAMA 1987. link 20 Yee ES, Schienman MM, Griffin JC, Ebert PA. Surgical options for treating ventricular tachyarrhythmia and sudden death. The Journal of thoracic and cardiovascular surgery 1987. link 21 Guarnieri T, Levine JH, Veltri EP, Griffith LS, Watkins L, Juanteguy J et al.. Success of chronic defibrillation and the role of antiarrhythmic drugs with the automatic implantable cardioverter/defibrillator. The American journal of cardiology 1987. link90352-3) 22 Sokoloff NM, Spielman SR, Greenspan AM, Rae AP, Brady PM, Kay HR et al.. Utility of ambulatory electrocardiographic monitoring for predicting recurrence of sustained ventricular tachyarrhythmias in patients receiving amiodarone. Journal of the American College of Cardiology 1986. link80360-6) 23 Reid PR, Griffith LS, Mower MM, Platia EV, Watkins L, Juanteguy J et al.. Implantable cardioverter-defibrillator: patient selection and implantation protocol. Pacing and clinical electrophysiology : PACE 1984. link 24 Pagé PL, Arciniegas JG, Plumb VJ, Henthorn RW, Karp RB, Waldo AL. Value of early postoperative epicardial programmed ventricular stimulation studies after surgery for ventricular tachyarrhythmias. Journal of the American College of Cardiology 1983. link80328-3) 25 Iseri LT, Chung P, Tobis J. Magnesium therapy for intractable ventricular tachyarrhythmias in normomagnesemic patients. The Western journal of medicine 1983. link 26 Schulte HD, Bircks W, Ostermeyer J, Seipel L. Surgery of life-threatening ventricular tachyarrhythmias associated with ventricular aneurysm. The Thoracic and cardiovascular surgeon 1979. link

Ventricular tachyarrhythmia